Abstract
Short‐ and long‐term experiments were designed to determine the effects of toremifene (TOR) on estrogen‐related endometrial carcinogenesis in mice. In the short‐term experiment, a single low dose of TOR (0.2 mg/30 g body weight) decreased expression of c‐fos, interleukin (IL)‐1α, estrogen receptor (ER)‐α mRNAs and corresponding proteins induced by estradiol‐l7β (E2), in the uteri of the ovariectomized mice. Expression of ER‐β mRNA was increased by the TOR treatment, compared with the control. In the long‐term experiment, 106 female ICR mice were given N‐methyl N‐nitrosourea (MNU) into their uterine corpora. The animals were divided into four groups as follows: group 1, E2 diet (5 ppm) plus TOR (0.2 mg/30 g body weight, subcutaneously, every four weeks); group 2, E2 diet alone; group 3, basal diet plus TOR. Group 4 served as the control. TOR treatment decreased the incidence of MNU and E2‐induced endometrial adenocarcinoma and atypical hyperplasia at the termination of the experiment (30 weeks after the start). These results suggest that TOR exerts preventive effects against estrogen‐related endometrial carcinogenesis in mice, through the suppression of c‐fos as well as IL‐1α expression induced by E2. Such suppressive effects of TOR may be related to the decreased ER‐α and increased ER‐β expressions.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.